Upstream Bio (NASDAQ:UPB) Shares Gap Down – Should You Sell?

Upstream Bio, Inc. (NASDAQ:UPB)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $27.81, but opened at $19.00. Upstream Bio shares last traded at $14.77, with a volume of 2,857,447 shares.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on UPB shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, January 21st. Truist Financial started coverage on Upstream Bio in a research note on Tuesday, October 14th. They issued a “buy” rating and a $47.00 price objective on the stock. Evercore started coverage on Upstream Bio in a research note on Tuesday, November 18th. They set an “outperform” rating and a $40.00 target price for the company. Mizuho raised Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. Finally, Lifesci Capital initiated coverage on Upstream Bio in a research report on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.25.

Upstream Bio Stock Down 46.2%

The business has a 50-day simple moving average of $29.17 and a two-hundred day simple moving average of $23.35. The stock has a market capitalization of $808.92 million, a P/E ratio of -7.94 and a beta of 1.90.

Institutional Trading of Upstream Bio

Several large investors have recently added to or reduced their stakes in the company. Bain Capital Life Sciences Investors LLC grew its holdings in shares of Upstream Bio by 6.3% during the second quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company’s stock worth $26,786,000 after purchasing an additional 144,216 shares during the last quarter. Geode Capital Management LLC grew its holdings in Upstream Bio by 57.5% during the 2nd quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock worth $7,101,000 after acquiring an additional 235,958 shares during the last quarter. Norges Bank acquired a new stake in Upstream Bio in the 2nd quarter valued at about $10,650,000. Virtus Investment Advisers LLC acquired a new stake in Upstream Bio in the 2nd quarter valued at about $89,000. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in shares of Upstream Bio by 133.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 7,833 shares of the company’s stock worth $86,000 after acquiring an additional 4,483 shares during the last quarter.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.